Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of XC243 in Exacerbation of Chronic Cystitis
NCT06391164Phase 2Not yet recruiting
- Sponsor
- PHARMENTERPRISES LLC
- Start
- Apr 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of XC243 in chronic cystitis (4 arms), sponsored by PHARMENTERPRISES LLC. Primary endpoint: Time from first dose until the symptom 'Pain, discomfort or burning when urination' disappears (decreases). Planned start Apr 2024; status: not yet recruiting.
02
Drugs
XC243
03
Conditions
chronic cystitis
Beyond the preview
Go deeper on NCT06391164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06391164.